BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Ozer, H.G., El-Gamal, D., Powell, B., Hing, Z.A., Blachly, J.S., Harrington, B., Mitchell, S., Grieselhuber, N.R., Williams, K., Lai, T.H., Alinari, L., Baiocchi, R.A., Brinton, L., Baskin, E., Cannon, M., Beaver, L., Goettl, V.M., Lucas, D.M., Woyach, J.A., Sampath, D., Lehman, A.M., Yu, L., Zhang, J., Ma, Y., Zhang, Y., Spevak, W., Shi, S., Severson, P., Shellooe, R., Carias, H., Tsang, G., Dong, K., Ewing, T., Marimuthu, A., Tantoy, C., Walters, J., Sanftner, L., Rezaei, H., Nespi, M., Matusow, B., Habets, G., Ibrahim, P., Zhang, C., Mathe, E.A., Bollag, G., Byrd, J.C., Lapalombella, R.
Cancer Discov